NMD Pharma shared new data from its Phase 2a SYNAPSE-CMT clinical trial evaluating the investigational drug ignaseclant during a late-breaking presentation at the 2026 MDA Clinical & Scientific Conference.
CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update
New Phase 2a CMT trial results are in. NMD Pharma shares details.
CMT Community Helps Achieve a Major Research Milestone with NMD Pharma
What happens when the CMT community takes action and participates in CMT research? NMD Pharma answers the question.
CMTA-STAR Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
The Phase II SYNAPSE-CMT clinical trial has launched, with the first patient dosed at a CMTA Center of Excellence in Austin, TX. The study is evaluating NMD670 in adults with CMT types 1 or 2 and is currently enrolling at sites in the U.S. and Europe.
CMTA | STAR Awards $354,826 For Charcot-Marie-Tooth Clinical Trial
CMTA-STAR has awarded $354,826 to support a clinical trial evaluating L-serine in patients with Hereditary Sensory Neuropathy 1, a rare form of CMT. Led by Dr. Mary Reilly at University College London, the study will assess disease progression using MRI muscle fat fraction as a primary outcome measure, advancing clinical trial readiness for inherited neuropathies.
